Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,696,564 | $6,413,740 | $6,395,392 | $6,479,811 |
| - Cash | $559,543 | $392,164 | $444,767 | $446,267 |
| + Debt | $856,616 | $743,058 | $617,568 | $209,922 |
| Enterprise Value | $7,993,637 | $6,764,634 | $6,568,193 | $6,243,466 |
| Revenue | $363,641 | $266,718 | $51,174 | $7,778 |
| % Growth | 36.3% | 421.2% | 557.9% | – |
| Gross Profit | $319,383 | $222,323 | $39,037 | $4,255 |
| % Margin | 87.8% | 83.4% | 76.3% | 54.7% |
| EBITDA | -$290,023 | -$411,168 | -$529,177 | -$364,642 |
| % Margin | -79.8% | -154.2% | -1,034.1% | -4,688.1% |
| Net Income | -$378,084 | -$481,447 | -$583,194 | -$383,577 |
| % Margin | -104% | -180.5% | -1,139.6% | -4,931.6% |
| EPS Diluted | -6.53 | -8.55 | -10.4 | -7 |
| % Growth | 23.6% | 17.8% | -48.6% | – |
| Operating Cash Flow | -$306,197 | -$467,361 | -$495,699 | -$417,649 |
| Capital Expenditures | -$1,427 | -$2,442 | -$14,489 | -$24,234 |
| Free Cash Flow | -$307,624 | -$469,803 | -$510,188 | -$441,883 |